Drug combinations of a heteroarotinoid (e.g., SHetA2, SHetA3, SHetA4, SHetC2, SHetD3, SHetD4, SHetD5, SHet50, SHet65, SHet100, OHet72, NHet17, NHet86, or NHet90), and an Azabicyclooctan-3-one derivative (e.g., PRIMA-1 or PRIMA.sup.MET) and/or a CDK4/6 inhibitor (e.g., Palbociclib, Abemaciclib, Ribociclib, Narazaciclib (ON123300), Dalpiciclib, Dinaciclib, Milciclib, Seliciclib), which are effective as anti-cancer treatments, and kits and methods of use of such drug combinations.

Drug combinations of a heteroarotinoid (e.g., SHetA2, SHetA3, SHetA4, SHetC2, SHetD3, SHetD4, SHetD5, SHet50, SHet65, SHet100, OHet72, NHet17, NHet86, or NHet90), and an Azabicyclooctan-3-one derivative (e.g., PRIMA-1 or PRIMA.sup.MET) and/or a CDK4/6 inhibitor (e.g., Palbociclib, Abemaciclib, Ribociclib, Narazaciclib (ON123300), Dalpiciclib, Dinaciclib, Milciclib, Seliciclib), which are effective as anti-cancer treatments, and kits and methods of use of such drug combinations.

The present disclosure relates generally to modulators of human glycolate oxidase enzyme and methods of use and manufacture thereof.

The present disclosure relates generally to modulators of human glycolate oxidase enzyme and methods of use and manufacture thereof.

The present disclosure provides compounds of Formula (I). The compounds described herein may be useful in treating a disease associated with IDO, for example, cancer or an infectious disease (e.g., viral or bacterial infectious diseases). Also, provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

The present disclosure provides compounds of Formula (I). The compounds described herein may be useful in treating a disease associated with IDO, for example, cancer or an infectious disease (e.g., viral or bacterial infectious diseases). Also, provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

The present invention is directed to the use of at least one SGLT-2 inhibitor in a non-human mammal, preferably ruminant, preferably for drying-off of a non-human mammal, preferably ruminant, as well as corresponding methods, such as improving and/or facilitating the drying-off of a non-human mammal, preferably ruminant, comprising administering to such non-human mammal, preferably ruminant, at least one SGLT-2 inhibitor.

The present invention is directed to the use of at least one SGLT-2 inhibitor in a non-human mammal, preferably ruminant, preferably for drying-off of a non-human mammal, preferably ruminant, as well as corresponding methods, such as improving and/or facilitating the drying-off of a non-human mammal, preferably ruminant, comprising administering to such non-human mammal, preferably ruminant, at least one SGLT-2 inhibitor.

An improved microparticle or lyophilized or otherwise reconstitutable microparticle composition thereof for medical therapy, including ocular therapy.

An improved microparticle or lyophilized or otherwise reconstitutable microparticle composition thereof for medical therapy, including ocular therapy.